Global Molecular Diagnostics Market Forecasts to 2026 - Point-of-Care (POC) Segment is Expected to Witness the Fastest Growth over the Forecast Period

Dublin, April 24, 2019 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics Market Size, Share & Trends Analysis Report By Technology, By Test Location, By Product (Instruments, Reagents), By Application (Oncology, Infectious Diseases), And Segment Forecasts, 2019 - 2026" report has been added to ResearchAndMarkets.com's offering.

The global molecular diagnostics market size is expected to reach USD 19.8 billion by 2026,progressing at a CAGR of 9.1% over the forecast period. Increasing prevalence of infectious diseases, such as human papillomavirus and influenza, is expected to be the primary force driving the market.

Instruments such as PCR and next generation sequencing platforms are widely preferred by central laboratories and diagnostic institutes due to rapid nature of these tests in delivering quick and reliable results and high volume of diagnostic procedures in this segment. Associated advantages including user-friendly nature of these tests and quick healthcare delivery are estimated to propel the point-of-care segment growth.

In underdeveloped regions of Africa and Nigeria, other infections such as HIV and tuberculosis are increasing at a high rate since the last few years. This is estimated to increase demand for early and accurate diagnostic techniques to curb their surge.

Molecular testing tools provide clinicians with better alternatives to detect countless infectious bacteria, virus, and pathogens in a short time while delivering highly accurate results. Initiatives led by organizations such as the WHO to conduct diagnostic programs in regions with high risk areas are estimated to be a high rendering driver.

Prenatal genetic testing, performed for the purpose of early detection of abnormalities that develop in the fetuses, is also expected to widen the client base for the molecular diagnostics market. Moreover, high adoption of unhealthy lifestyles resulting in a large patient count afflicted with chronic diseases such as diabetes and cardiovascular disorders is projected to positively impact the growth.

Rising healthcare spending, increasing awareness among patients, and expansion of R&D activities related to drug discovery and development are expected to drive the market in North America and Europe. Rising demand for improved diagnostic technologies employed for the prevention of epidemics, unaddressed clinical needs, and recent activities by key players targeting expansion in this region are the major factors supporting the market growth in Asia Pacific.

Key players are advancing strategic collaborations with major technology-based companies and diagnostic centers and tapping developing regions in an attempt to increase their market share and attain stability.

Further key findings from the study suggest:

• On the basis of product, reagents were the largest revenue generating segment in 2018 owing to their elevated usage rates. Reagents are key products used in academic and research institutes to perform various molecular biology protocols, further contributing towards the growth of this segment
• Based on test location, central laboratories led the market with the largest market share in 2018 owing to their established base in the remote and developing regions. The point-of-care segment is expected to witness the fastest growth over the forecast period
• On the basis of application, infectious diseases dominated the overall molecular diagnostics market in 2018. The oncology application segment is expected to exhibit a CAGR of around 11.8% over the forecast period due to rising awareness among people as well as healthcare professionals pertaining to cancer diagnosis
• Based on technology, the polymerase chain reaction (PCR) dominated the market in terms of revenue in 2018, attributed to growing applications of multiplex PCR over the conventional PCR procedure and introduction of easy-to-use PCR handling kits
• North America emerged as the largest regional segment in 2018, followed by Europe, primarily driven by well-established healthcare infrastructure. Asia Pacific is expected witness the fastest growth over the forecast period
• Some of the major players are Novartis AG (Grifols); Siemens Healthcare GmbH; Bio-Rad Laboratories, Inc.; Alere, Inc.; Danaher Corporation; BioMerieux SA; Sysmex Corporation; Becton; Dickinson and Company; Johnson & Johnson Services, Inc.; Bio-Rad Laboratories, Inc.; Bayer AG, Qiagen; Hologic, Inc. (Gen Probe); Cepheid; F. Hoffmann-La Roche Ltd; and Dako

Topics Covered

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Internal database
1.3.3. Secondary sources & Third party perspectives
1.3.4. Primary research
1.4. Information Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Molecular Diagnostics Market Variables, Trends & Scope
3.1. Molecular Diagnostics Market Lineage outlook
3.1.1. IVD market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Regulatory Framework
3.3.1. Reimbursement framework
3.3.2. Standards & compliances
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.2. Market restraint analysis
3.5. Molecular Diagnostics Market Analysis Tools
3.5.1. Industry analysis - Porter's
3.5.2. PESTEL analysis
3.5.3. Major deals & strategic alliances analysis

Chapter 4. Molecular Diagnostics Market - Competitive Analysis
4.1. Recent Developments & Impact Analysis, by Key Market Participants
4.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
4.3. Vendor Landscape
4.3.1. List of key distributors and channel partners
4.3.2. Key company market share analysis, 2018
4.4. Public Companies
4.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
4.4.2. Company market share
4.4.3. Competitive dashboard analysis
4.4.4. Market differentiators
4.4.5. Synergy analysis: Major deals & strategic alliances
4.5. Private Companies
4.5.1. List of key emerging companies
4.5.2. Regional network map
4.5.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)

Chapter 5. Molecular Diagnostics Market: Product Estimates & Trend Analysis
5.1. Definitions & Scope
5.2. Product Market Share Analysis, 2018 & 2026
5.3. Molecular Diagnostics Market, by Product, 2014 to 2026
5.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
5.4.1. Instruments
5.4.2. Reagents
5.4.3. Others

Chapter 6. Molecular Diagnostics Market: Test Location Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. Test Location Market Share Analysis, 2018 & 2026
6.3. Molecular Diagnostics Market, by Test Location, 2014 to 2026
6.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
6.4.1. Point of care
6.4.2. Self-test or OTC
6.4.3. Central laboratories

Chapter 7. Molecular Diagnostics Market: Technology Estimates & Trend Analysis
7.1. Definitions & Scope
7.2. Technology Market Share Analysis, 2018 & 2026
7.3. Molecular Diagnostics Market, by Technology, 2014 to 2026
7.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following:
7.4.1. PCR
7.4.2. ISH
7.4.3. INAAT
7.4.4. Chips and microarrays
7.4.5. Mass spectrometry
7.4.6. Sequencing
7.4.7. TMA
7.4.8. Others
7.5. Technology Markets, by Product, 2014 to 2026:
7.5.1. PCR
7.5.2. ISH
7.5.3. INAAT
7.5.4. Chips and microarrays
7.5.5. Mass spectrometry
7.5.6. Sequencing
7.5.7. TMA
7.5.8. Others

Chapter 8. Molecular Diagnostics Market: Application Estimates & Trend Analysis
8.1. Definitions & Scope
8.2. Application Market Share Analysis, 2018 & 2026
8.3. Molecular Diagnostics Market, by Application, 2014 to 2026
8.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following:
8.4.1. Oncology
8.4.2. Pharmacogenomics
8.4.3. Infectious disease
8.4.4. Genetic testing
8.4.5. Neurological disease
8.4.6. Cardiovascular disease
8.4.7. Microbiology
8.4.8. Others

Chapter 9 Molecular Diagnostics Market: Regional Estimates & Trend Analysis, by Product, Test Location, Technology, & Application
9.1 Molecular Diagnostics Market: Regional Movement Analysis, 2018 & 2026
9.2 Molecular Diagnostics Market: Leading Players, 2018:
9.3 SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
9.4 North America
9.5. Europe
9.6 Asia Pacific
9.7 Latin America
9.8 MEA

Chapter 10 Competitive Landscape
10.1 Strategy Framework
10.2 Heat Map Analysis of Private Companies
10.3 Abbott
10.4 Becton, Dickinson and Company
10.5 bioMerieux S.A.
10.6 Bio-Rad Laboratories Inc.
10.7 Dako
10.8 Danaher Corporation
10.9 Hologic Inc. (Gen Probe)
10.10 Illumina Inc.
10.11 Johnson & Johnson Services Inc.
10.12 Novartis (Grifols)
10.13 Qiagen
10.14 Roche Diagnostics
10.15 Siemens Healthcare Private Limited
10.16 Sysmex Corporation

For more information about this report visit https://www.researchandmarkets.com/r/6muqmx

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Molecular Diagnostics